Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations: Investors Who Have Lost Money Are Encouraged to Contact the Firm

Error message

Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Milestone Pharmaceuticals, Inc. (NASDAQ: MIST) for potential securities law violations.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Thursday, January 18, 2024

Information

Tags:

Letter, Block & Leviton, New Drug Application, Food, Waste, Milestone, Agency, RFT, FDA, Pharmaceutical industry

Geotags:

BOSTON, MA, US

⚠ partially generated by AI ↴

Organisation:

BLOCK & LEVITON, BLOCK & LEVITON LLP, MILESTONE PHARMACEUTICALS

Stock Symbol:

NASDAQ:MIST

Summary

Key Points:

BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Milestone Pharmaceuticals, Inc. (NASDAQ: MIST) for potential securities law violations.
Investors who have lost money in their Milestone Pharmaceuticals, Inc. investment should contact the firm to learn more about how they might recover those losses.
Anyone who purchased Milestone Pharmaceuticals, Inc. stock and has lost money may be eligible, whether or not they have sold their investment.
Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.

BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Milestone Pharmaceuticals, Inc. (NASDAQ: MIST) for potential securities law violations. Investors who have lost money in their Milestone Pharmaceuticals, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/mist.

What is this all about?

Before the market opened on December 26, 2023, Milestone Pharmaceuticals, Inc. announced that it had received a Refuse to File (“RFT”) letter from the U.S. Food and Drug Administration (“FDA”) for its recently submitted New Drug Application for its lead candidate, Etripamil. In the RFT, the FDA noted that Milestone had not provided the Agency with sufficient information to begin its review and sought additional information related to the timing of adverse events in the Company’s Phase 3 trial.

Shares of Milestone Pharmaceuticals, Inc. stock dropped 28% in premarket trading on December 26, 2023.

Who is eligible?

Anyone who purchased Milestone Pharmaceuticals, Inc. stock and has lost money may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.

What is Block & Leviton doing?

Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.

What should you do next?

If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at [email protected], or by phone at (617) 398-5600.

Why should you contact Block & Leviton?

Block & Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website, www.blockleviton.com, or call (617) 398-5600 or email [email protected] with any questions.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: [email protected]

SOURCE: Block & Leviton LLP
www.blockleviton.com